DMK Pharmaceuticals (DMK Pharmaceuticals) Risk Assessment

View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of DMK Pharmaceuticals is: No Data: Cannot be evaluated.

Competitive Comparison of DMK Pharmaceuticals's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMK Pharmaceuticals's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's Risk Assessment falls into.

DMK Pharmaceuticals (OTCPK:DMKPQ) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

DMK Pharmaceuticals Risk Assessment Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

0A4X:UK

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

Executives

Dorbin John W. Jr.	officer: General Counsel	C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen	officer: CFO	C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi	director, officer: CEO	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi	director	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed	director	TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio	director	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd	director, 10 percent owner, officer: President/CEO	PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss	officer: Chief Medical Officer	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto	officer: Chief Financial Officer	11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai	director	1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins	officer: Chief Financial Officer	2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels	officer: Vice President of Operations	11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf	director	C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt	director	11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams	director	26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134